Evidence map›Paper›PMID 30718510›Full record

ArticleCell death & disease2019

CEMIP (KIAA1199) induces a fibrosis-like process in osteoarthritic chondrocytes.

Céline Deroyer, Edith Charlier, Sophie Neuville, Olivier Malaise, Philippe Gillet, William Kurth, Alain Chariot, Michel Malaise, Dominique de Seny

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Pirfenidone Attenuates Fibrosis and Neovascularization in 3D Spheroid-Laden Hydrogel Culture.Journal of tissue engineering and regenerative medicine · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Céline DeroyerLaboratory of Rheumatology, GIGA I3, CHU de Liege, University of Liege, Liege, Belgium. celine.deroyer@chuliege.be.
Edith CharlierLaboratory of Rheumatology, GIGA I3, CHU de Liege, University of Liege, Liege, Belgium.
Sophie NeuvilleLaboratory of Rheumatology, GIGA I3, CHU de Liege, University of Liege, Liege, Belgium.
Olivier MalaiseLaboratory of Rheumatology, GIGA I3, CHU de Liege, University of Liege, Liege, Belgium.
Philippe GilletOrthopedic Surgery Unit, CHU of Liege, Belgium.
William KurthOrthopedic Surgery Unit, CHU of Liege, Belgium.
Alain ChariotLaboratory of Medical Chemistry, GIGA Molecular Biology of Diseases, University of Liege, Liege, Belgium.
Michel MalaiseLaboratory of Rheumatology, GIGA I3, CHU de Liege, University of Liege, Liege, Belgium.
Dominique de SenyLaboratory of Rheumatology, GIGA I3, CHU de Liege, University of Liege, Liege, Belgium.
Centre Hospitalier Universitaire de Liège · BEUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CEMIP (for "Cell migration-inducing protein" also called KIAA1199 and Hybid for "Hyaluronan-binding protein") expression is increased in cancers and described as a regulator of cell survival, growth and invasion. In rheumatoid arthritis, CEMIP is referred to as an angiogenic marker and participates in hyaluronic acid degradation. In this study, CEMIP expression is investigated in healthy and osteoarthritis (OA) cartilage from human and mouse. Its role in OA physiopathology is deciphered, specifically in chondrocytes proliferation and dedifferentiation and in the extracellular matrix remodeling. To this end, CEMIP, αSMA and types I and III collagen expressions were assessed in human OA and non-OA cartilage. CEMIP expression was also investigated in a mouse OA model. CEMIP expression was studied in vitro using a chondrocyte dedifferentiation model. High-throughput RNA sequencing was performed on chondrocytes after CEMIP silencing. Results showed that CEMIP was overexpressed in human and murine OA cartilage and along chondrocytes dedifferentiation. Most of genes deregulated in CEMIP-depleted cells were involved in cartilage turnover (e.g., collagens), mesenchymal transition and fibrosis. CEMIP regulated β-catenin protein level. Moreover, CEMIP was essential for chondrocytes proliferation and promoted αSMA expression, a fibrosis marker, and TGFβ signaling towards the p-Smad2/3 (Alk5/PAI-1) pathway. Interestingly, CEMIP was induced by the pSmad1/5 (Alk1) pathway. αSMA and type III collagen expressions were overexpressed in human OA cartilage and along chondrocytes dedifferentiation. Finally, CEMIP was co-expressed in situ with αSMA in all OA cartilage layers. In conclusion, CEMIP was sharply overexpressed in human and mouse OA cartilage and along chondrocytes dedifferentiation. CEMIP-regulated transdifferentiation of chondrocytes into "chondro-myo-fibroblasts" expressing α-SMA and type III collagen, two fibrosis markers. Moreover, these "chondro-myo-fibroblasts" were found in OA cartilage but not in healthy cartilage.

Indexed as

ActinsAdultAgedAged, 80 and overAnimalsbeta CateninCartilage, ArticularCell DifferentiationCell ProliferationCells, CulturedChondrocytesCollagen Type ICollagen Type IIIDisease Models, AnimalExtracellular MatrixFemaleActa2 protein, mouseActinsbeta CateninCEMIP protein, humanCollagen Type ICollagen Type IIIHyaluronoglucosaminidaseSmad2 ProteinSMAD2 protein, humanTransforming Growth Factor beta

Identifiers

PMID30718510
PMCPMC6362103
OpenAlexW2912489217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.